{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T16:23:34Z","timestamp":1787847814104,"version":"build-2784847793"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Lung adenocarcinoma is a common malignancy that requires new treatments. Arsenic trioxide (ATO) exerts antitumor activity in various cancers; however, its mechanisms of action in lung adenocarcinoma remain unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>The 24-h half-maximal inhibitory concentration (IC50) of ATO on human lung adenocarcinoma A549 cells was determined using the Cell Counting Kit-8 assay. Cells were treated with the IC50 concentration in the experimental group, and untreated cells served as the control group. A comparative assessment of cell proliferation, apoptosis, invasion, and migration was performed. Transcriptome sequencing followed by Gene Ontology and Kyoto Encyclopedia of Genes and Genomes enrichment analyses were conducted to identify differentially expressed genes and enriched pathways. Candidate pathway proteins were validated by western blot analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      The 24-h IC50 of ATO was 99.12 \u03bcmol\/L. The ATO-treated group exhibited reduced proliferation, increased apoptosis, and decreased invasion and migration (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.05) compared with that in the control group. Transcriptome analysis revealed 4,522 upregulated and 4,045 downregulated genes, with enrichment in the mammalian target of rapamycin (mTOR) signaling pathway, base excision repair (BER), and apoptosis pathways. At the protein level, total mTOR expression did not significantly change, whereas phosphorylated mTOR (p-mTOR), APE-1, Bcl-2, and Bcl-XL were downregulated, and cleaved caspase-8 and cleaved caspase-9 were upregulated (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.05).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion:<\/jats:title>\n                    <jats:p>These results indicate that ATO suppresses the malignant phenotype of A549 cells by inhibiting mTOR phosphorylation, downregulating key BER components, and activating the extrinsic and intrinsic apoptotic pathways, providing experimental evidence for further studies of ATO in lung adenocarcinoma therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/jcrt.jcrt_2379_25","type":"journal-article","created":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T07:00:48Z","timestamp":1779951648000},"page":"383-389","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["A study on the antitumor effect and mechanism of arsenic trioxide on lung adenocarcinoma"],"prefix":"10.4103","volume":"22","author":[{"given":"Qixian","family":"Zheng","sequence":"first","affiliation":[{"name":"Department of Pulmonary and Critical Care Medicine, Fujian Medical University Union Hospital, Fuzhou, Fujian, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyu","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Pulmonary and Critical Care Medicine, Fujian Medical University Union Hospital, Fuzhou, Fujian, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianyuan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Oncology Medicine, Fujian Medical University Union Hospital, Fuzhou, Fujian, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ningjing","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Oncology Medicine, Fujian Medical University Union Hospital, Fuzhou, Fujian, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiong","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Oncology Medicine, Fujian Medical University Union Hospital, Fuzhou, Fujian, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Oncology Medicine, Fujian Medical University Union Hospital, Fuzhou, Fujian, P.R. China"},{"name":"Fujian Key Laboratory of Translational Research in Cancer and Neurodegenerative Diseases, Fuzhou, Fujian, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suyun","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Oncology Medicine, Fujian Medical University Union Hospital, Fuzhou, Fujian, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangqi","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Pulmonary and Critical Care Medicine, Fujian Medical University Union Hospital, Fuzhou, Fujian, P.R. China"},{"name":"Fujian Key Laboratory of Translational Research in Cancer and Neurodegenerative Diseases, Fuzhou, Fujian, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Traditional Chinese Medicin, Fujian Medical University Union Hospital, Fuzhou, Fujian, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,5,27]]},"reference":[{"key":"R1-20260528","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.4103\/jcrt.jcrt_973_23","article-title":"Surgery or radiotherapy improves survival in elderly patients with early non-small cell lung cancer: A population-based analysis","volume":"20","author":"Shi","year":"2024","journal-title":"J Cancer Res Ther"},{"key":"R2-20260528","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA A Cancer J Clin"},{"key":"R3-20260528","doi-asserted-by":"crossref","first-page":"782","DOI":"10.4103\/jcrt.jcrt_1431_22","article-title":"KRAS and BRAF genetic alterations in lung cancer: A case - control study","volume":"20","author":"Sawal","year":"2024","journal-title":"J Cancer Res Ther"},{"key":"R4-20260528","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S0140-6736(21)00312-3","article-title":"Lung cancer","volume":"398","author":"Thai","year":"2021","journal-title":"Lancet"},{"key":"R5-20260528","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.ejphar.2018.07.034","article-title":"Molecular targeted therapy: Treating cancer with specificity","volume":"834","author":"Lee","year":"2018","journal-title":"Eur J Pharmacol"},{"key":"R6-20260528","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1016\/S0140-6736(16)00587-0","article-title":"Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): A multicentre, open-label, phase 2 randomised controlled trial","volume":"387","author":"Fehrenbacher","year":"2016","journal-title":"Lancet"},{"key":"R7-20260528","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/s41571-019-0173-9","article-title":"Comparing and contrasting predictive biomarkers for immunotherapy and targeted therapy of NSCLC","volume":"16","author":"Camidge","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"R8-20260528","doi-asserted-by":"crossref","first-page":"23905","DOI":"10.18632\/oncotarget.14733","article-title":"Metabolism, toxicity and anticancer activities of arsenic compounds","volume":"8","author":"Khairul","year":"2017","journal-title":"Oncotarget"},{"key":"R9-20260528","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1039\/c9mt00308h","article-title":"Therapeutic strategy of arsenic trioxide in the fight against cancers and other diseases","volume":"12","author":"Wang","year":"2020","journal-title":"Metallomics"},{"key":"R10-20260528","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/35077213","article-title":"Proliferation, cell cycle and apoptosis in cancer","volume":"411","author":"Evan","year":"2001","journal-title":"Nature"},{"key":"R11-20260528","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.tiv.2008.11.011","article-title":"Increased aquaglyceroporin 9 expression disrupts arsenic resistance in human lung cancer cells","volume":"23","author":"Miao","year":"2009","journal-title":"Toxicol Vitro"},{"key":"R12-20260528","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.3390\/cimb45030120","article-title":"Revealing the History and Mystery of RNA-Seq","volume":"45","author":"Gondane","year":"2023","journal-title":"Current Issues In Molecular Biology"},{"key":"R13-20260528","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.ygyno.2018.10.002","article-title":"RNA sequencing (RNA-Seq) and its application in ovarian cancer","volume":"152","author":"Wang","year":"2019","journal-title":"J Gynecol Oncol"},{"key":"R14-20260528","doi-asserted-by":"crossref","first-page":"e0116771","DOI":"10.1371\/journal.pone.0116771","article-title":"The prognostic role of mTOR and p-mTOR for survival in non-small cell lung cancer: A systematic review and meta-analysis","volume":"10","author":"Li","year":"2015","journal-title":"PLoS One"},{"key":"R15-20260528","doi-asserted-by":"crossref","first-page":"755","DOI":"10.3390\/ijms20030755","article-title":"mTOR Signaling in Cancer and mTOR Inhibitors in Solid Tumor Targeting Therapy","volume":"20","author":"Tian","year":"2019","journal-title":"Int J Mol Sci"},{"key":"R16-20260528","doi-asserted-by":"crossref","first-page":"973","DOI":"10.3892\/or.2014.3276","article-title":"Anti-apoptotic and apoptotic pathway analysis of arsenic trioxide-induced apoptosis in human gastric cancer SGC-7901 cells","volume":"32","author":"Yu","year":"2014","journal-title":"Oncol Rep"},{"key":"R17-20260528","doi-asserted-by":"crossref","first-page":"3969","DOI":"10.1007\/s13277-015-3040-z","article-title":"Arsenic trioxide inhibits growth of human chondrosarcoma cells through G2\/M arrest and apoptosis as well as autophagy","volume":"36","author":"Jiao","year":"2015","journal-title":"Tumor Biol"},{"key":"R18-20260528","doi-asserted-by":"crossref","first-page":"111116","DOI":"10.1016\/j.celrep.2022.111116","article-title":"Acetylation of p62 regulates base excision repair through interaction with APE1","volume":"40","author":"Li","year":"2022","journal-title":"Cell Rep"},{"key":"R19-20260528","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1042\/EBC20200013","article-title":"Base excision repair and its implications to cancer therapy","volume":"64","author":"Grundy","year":"2020","journal-title":"Essays Biochem"},{"key":"R20-20260528","doi-asserted-by":"crossref","first-page":"102769","DOI":"10.1016\/j.dnarep.2019.102769","article-title":"The splicing component ISY1 regulates APE1 in base excision repair","volume":"86","author":"Jaiswal","year":"2020","journal-title":"DNA Repair (Amst)"},{"key":"R21-20260528","doi-asserted-by":"crossref","first-page":"2876","DOI":"10.1038\/onc.2013.251","article-title":"Functional regulation of the apurinic\/apyrimidinic endonuclease 1 by nucleophosmin: Impact on tumor biology","volume":"33","author":"Vascotto","year":"2014","journal-title":"Oncogene"},{"key":"R22-20260528","first-page":"11709","article-title":"Lamin A\/C promotes DNA base excision repair","volume":"47","author":"Maynard","year":"2019","journal-title":"Nucleic Acids Res"},{"key":"R23-20260528","first-page":"1","article-title":"Evaluation of Arsenic Trioxide Potential for Lung Cancer Treatment: Assessment of Apoptotic Mechanisms and Oxidative Damage","volume":"8","author":"Walker","year":"2016","journal-title":"J Cancer Res Ther"},{"key":"R24-20260528","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/1756-9966-30-87","article-title":"Apoptosis in cancer from pathogenesis to treatment","volume":"30","author":"Wong","year":"2011","journal-title":"J Exp Clin Cancer Res"},{"key":"R25-20260528","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/1477-7819-8-31","article-title":"The conformation change of Bcl-2 is involved in arsenic trioxide-induced apoptosis and inhibition of proliferation in SGC7901 human gastric cancer cells","volume":"8","author":"Zheng","year":"2010","journal-title":"World J Surg Oncol"},{"key":"R26-20260528","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/jcb.20102","article-title":"Inhibition of cell proliferation and the action mechanisms of arsenic trioxide (As2O3) on human breast cancer cells","volume":"93","author":"Chow","year":"2004","journal-title":"J Cell Biochem"},{"key":"R27-20260528","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.1158\/1078-0432.CCR-03-0309","article-title":"Arsenic trioxide-induced death of neuroblastoma cells involves activation of Bax and does not require p53","volume":"10","author":"Karlsson","year":"2004","journal-title":"Clin Cancer Res"},{"key":"R28-20260528","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/S0090-4295(02)01699-0","article-title":"Cytotoxicity of arsenic trioxide to transitional carcinoma cells","volume":"60","author":"Pu","year":"2002","journal-title":"Urology"},{"key":"R29-20260528","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.3892\/ijo.2014.2609","article-title":"E2F1 downregulation by arsenic trioxide in lung adenocarcinoma","volume":"45","author":"Lam","year":"2014","journal-title":"Int J Oncol"},{"key":"R30-20260528","doi-asserted-by":"crossref","first-page":"3748","DOI":"10.3892\/ol.2017.6646","article-title":"Tumour growth-suppressive effect of arsenic trioxide in squamous cell lung carcinoma","volume":"14","author":"Leung","year":"2017","journal-title":"Oncol Lett"},{"key":"R31-20260528","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1007\/s12094-019-02054-6","article-title":"A candidate for lung cancer treatment: Arsenic trioxide","volume":"21","author":"Huang","year":"2019","journal-title":"Clin Transl Oncol"}],"container-title":["Journal of Cancer Research and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.jcrt_2379_25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T15:39:21Z","timestamp":1787845161000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.jcrt_2379_25"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.4103\/jcrt.jcrt_2379_25","relation":{},"ISSN":["0973-1482","1998-4138"],"issn-type":[{"value":"0973-1482","type":"print"},{"value":"1998-4138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"2025-11-23","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-02","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}